Last update Feb. 11, 2019
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
ロキソプロフェンナトリウム is Loxoprofen Sodium in Japanese.Is written in other languages:
ロキソプロフェンナトリウム belongs to this group or family:
Main tradenames from several countries containing ロキソプロフェンナトリウム in its composition:
|Tmax||0.5 - 0.8||hours|
|T½||1.3 - 1.6||hours|
Write us at firstname.lastname@example.org
e-lactancia is a resource recommended by Asociación Pro Lactancia Materna (APROLAM) of Mexico
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
A non-steroidal anti-inflammatory derivative of propionic acid with prostaglandin inhibitory effect due to non-selective inhibition of cyclo-oxygenase, used in the oral and topical treatment of pain and inflammatory and febrile processes.
Oral administration, one to three times a day.
Since the last update date we have not found published data on its excretion in breastmilk.
Its pharmacokinetic data - high percentage of protein binding, short life (DrugInfo 2018, Helmy 2013, Jhee 2007) and low pKa - means it is unlikely for there to be transfer to milk in significant amounts.
Until there is more published data on this drug in relation to breastfeeding, safer alternatives may be preferred, especially during the neonatal period and in cases of prematurity.